Kerala faces a growing public‑health challenge as snakebite deaths rise despite the widespread availability of ASV. The problem stems from ecological factors, clinical decision‑making uncertainties, and infrastructural shortfalls that together undermine the effectiveness of treatment.
Key Developments
- Hotter pre‑monsoon summers drive ectothermic snakes into homes and storerooms, increasing human contact.
- The Indian Council of Medical Research (ICMR) has highlighted the flaws of the current syndromic approach, which relies on symptoms that appear after irreversible tissue damage.
- Kerala’s SARPA initiative has made snakebite a notifiable disease and launched rescue‑training programmes, yet mortality remains high.
- Administration of ASV carries a risk of anaphylaxis, complicating treatment decisions.
Important Facts
India records nearly 50% of global snakebite incidents, with agricultural workers and children most vulnerable. Kerala alone hosts over 100 snake species, including the “Big Four” venomous snakes – the common krait, Russell’s viper, saw‑scaled viper and spectacled cobra. Approximately 70% of bites involve non‑venomous snakes, and half of the venomous bites are “dry” (no venom injected), meaning many patients do not require ASV. However, the lack of a rapid diagnostic kit forces clinicians to rely on symptom‑based assessment, often leading to delayed or unnecessary treatment.
Compounding the issue are scarce ICU beds, limited ventilator backups, inadequate training in managing